Comparison
Carbetocin vs. Glepaglutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
37025-55-1
no data
Molecular weight
no data
no data
Half-life
0.67 h
no data
Sequence
no data
no data
Mechanism of action
Carbetocin
Carbetocin is an oxytocin receptor agonist with prolonged duration. It triggers a sustained contraction of the uterus after birth, preventing atonic hemorrhage — unlike oxytocin, without a multi-hour infusion.
Glepaglutide
As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
1
of which in humans
1
1
Effects recorded
2
2
Open conflicts
0
0
Documented adverse events
1
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Carbetocin and Glepaglutide?
- Carbetocin is classified as "Research other", while Glepaglutide is classified as "Research other". Carbetocin: Carbetocin is a long-acting synthetic oxytocin analog (half-life ~40 minutes). It prevents postpartum hemorrhage as a single injection. Approved in Canada and the UK among others, NOT in the US. Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Carbetocin or Glepaglutide?
- The highest available evidence level is "Human RCT" for Carbetocin and "Human RCT" for Glepaglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Carbetocin and Glepaglutide in Germany and the United States?
- Germany: Carbetocin — Prescription, Glepaglutide — Unapproved. United States: Carbetocin — Unapproved, Glepaglutide — Unapproved. These are factual summaries with source and review date on the individual pages.